Back to Journals » Cancer Management and Research » Volume 1

The role of azacitidine in the management of myelodysplastic syndromes (MDS)

Authors Goetze K, Müller-Thomas C, Peschel C

Published 9 October 2009 Volume 2009:1 Pages 119—130

DOI https://doi.org/10.2147/CMAR.S4721

Review by Single anonymous peer review

Peer reviewer comments 2



KS Götze, C Müller-Thomas, C Peschel

Department of Medicine, Hematology/Oncology, Technische Universität München, Munich, Germany

Abstract: Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a propensity for transformation to acute myeloid leukemia (AML). For many years, the main treatment option for MDS was best supportive care which alleviates symptoms but has no effect on the natural course of the disease. The recent approval of the demethylating agent azacitidine represents a significant advance in the treatment of MDS. The results of two randomized trials with azacitidine have shown an overall response rate between 40% and 60%, an improved quality of life, a reduced risk of transformation to AML and a definite survival advantage compared to best supportive care or low-dose chemotherapy. Current data on azacitidine and its place in the treatment of MDS are reviewed.

Keywords: myelodysplastic syndromes, MDS, azacitidine, epigenetic therapy, demethyltransferase inhibitor

Creative Commons License © 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.